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Statement of translational relevance   
 
Nelfinavir, a PI3-kinase pathway inhibitor, is a radiosensitizer which increases tumor 
blood flow in preclinical models. This early-phase study demonstrates the safety of 
nelfinavir combined with radiation therapy (RT) for rectal cancer.  It includes the 
development of imaging biomarkers of tumor perfusion and a tissue biomarker of 
radiosensitization which can be measured in biopsy tissue taken before and after 
treatment.  Based on the results of this study, the efficacy of nelfinavir-RT versus RT 
alone merits phase II evaluation in the treatment of rectal cancer, including 
measurement of tumor blood flow.  
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Abstract  
Purpose 
Nelfinavir, a PI3-kinase pathway inhibitor, is a radiosensitizer which increases tumor 
blood flow in preclinical models. We conducted an early-phase study to demonstrate 
the safety of nelfinavir combined with hypofractionated radiotherapy (RT) and to 
develop biomarkers of tumor perfusion and radiosensitization for this combinatorial 
approach. 
Patients and Methods 
Ten patients with T3-4 N0-2 M1 rectal cancer received 7 days of oral nelfinavir (1250 
mg bd) and a further 7 days of nelfinavir during pelvic RT (25 Gy/5 fractions/7 days).  
Perfusion CT (p-CT) and DCE-MRI scans were performed pre-treatment, after 7 
days of nelfinavir and prior to last fraction of RT.  Biopsies taken pre-treatment and 7 
days after the last fraction of RT were analysed for tumor cell density (TCD).   
Results 
There were 3 drug-related grade 3 adverse events: diarrhea, rash, lymphopenia.  On 
DCE-MRI, there was a mean 42% increase in median Ktrans, and a corresponding 
median 30% increase in mean blood flow on p-CT during RT in combination with 
nelfinavir. Median TCD decreased from 24.3% at baseline to 9.2% in biopsies taken 
7 days after RT (P=0.01).2YHUDOOHYDOXDEOHSDWLHQWVH[KLELWHGJRRGtumor 
regression RQ05,DVVHVVHGE\7XPRU5HJUHVVLRQ*UDGHPU75*. 
&RQFOXVLRQV 
This is the first study to evaluate nelfinavir in combination with RT without concurrent 
chemotherapy.  It has shown that nelfinavir-RT is well tolerated and is associated 
with increased blood flow to rectal tumors.  The efficacy of nelfinavir-RT versus RT 
alone merits clinical evaluation, including measurement of tumor blood flow.   
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Introduction 
Pelvic radiotherapy (RT) has an important role in the treatment of patients with rectal 
adenocarcinoma. Short course RT, 25 Gy delivered in 5 daily fractions in one week 
followed by surgery within 5-7 days, can halve the risk of local recurrence in patients 
with operable rectal cancer(1, 2). Long-course pre-operative chemo-radiotherapy 
(LCCRT), typically 45-50.4 Gy in 25-28 daily fractions over 5-6 weeks in combination 
with 5-fluorouracil or capecitabine as a radiosensitizer, is generally offered to 
patients with locally advanced tumors.  Tumor regression has been shown to 
correlate with improved outcomes for patients(3-5).  
The optimal first treatment for patients with a symptomatic primary rectal cancer and 
distant metastases at presentation is a matter of debate. Systemic therapy is not 
effective in all patients; although it may achieve response after 6-8 weeks of therapy, 
it does not provide rapid symptom relief for all patients(6).  Planning and delivery of 
LCCRT may delay delivery of full-dose systemic therapy and may therefore 
compromise surgical treatment of metastatic disease (e.g. liver surgery for operable 
metastases). A strategy of short-course RT followed 2 weeks later by full-dose 
systemic combination chemotherapy can be used to prevent this delay.  Short-
course RT can safely precede full-dose systemic therapy (e.g. capecitabine and 
oxaliplatin and bevacizumab), resulting in pathological complete response (pCR) 
rates above 25% and radical resection and/or radiofrequency ablation of all 
metastatic disease in the majority of patients(7).  
One factor increasing cellular resistance to RT is over-expression of activated 
oncogenes, such as the epidermal growth factor receptor (EGFR)(8), RAS(9)  or loss 
of the tumor suppressor gene PTEN(10). These mutations share molecular signaling 
via the phosphatidylinositol 3-kinase (PI3K)-Akt-pathway.  We have previously 
shown that inhibition of this pathway augments response to RT in vitro and in vivo in 
cells with constitutive activation of this pathway, an effect not seen in cells with a 
non-activated pathway(11-14). This pathway is frequently altered in humans with 
colorectal cancer (CRC)(15).  Since the PI3K signaling pathway can be constitutively 
activated in tumor cells, yet not in host cells, an inhibitor of this pathway might be 
expected to improve the therapeutic index through selective tumor 
radiosensitization(16).  
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Nelfinavir is an HIV-protease inhibitor (HPI) which has been shown to inhibit Akt at 
standard clinical doses and to cause radiosensitization in vivo(17). In addition to 
intrinsic radiosensitization, we have shown previously that nelfinavir caused 
sustained improvements in tumor perfusion and reduction in hypoxia in a mouse 
xenograft model(18).  Although some clinical studies have investigated nelfinavir in 
combination with chemoradiotherapy (see Table 1), there are no published data on 
the addition of nelfinavir to RT without concomitant chemotherapy.  Nor are there 
data on whether the changes in perfusion observed in pre-clinical studies with 
nelfinavir are replicated in human subjects with cancer.  Dynamic contrast-enhanced 
MRI (DCE-MRI) and perfusion CT (p-CT) have previously been used to detect 
changes in tumor perfusion induced by anti-angiogenic drugs(19, 20) and 
chemoradiotherapy for rectal cancer(21-25).   
A barrier to the advancement of radiosensitizers is uncertainty regarding the optimal 
primary endpoint for clinical trials. Endpoints traditionally used, such as pCR rate, 
radiological response or disease free survival, have a number of limitations, including 
variability of definitions(26). The development of new tissue biomarkers of response 
is highly desirable for the evaluation of novel radiosensitizers. We have developed a 
quantitative assessment of tumor cell density (TCD) which is a predictor of survival in 
patients with CRC(27). We are currently exploring this technique to compare 
different pre-operative RT schedules(28).  
The objective of the SONATINA (Study Of Nelfinavir Addition to Radiotherapy 
Treatment In Neo-Adjuvant Rectal Cancer) clinical trial was to investigate the safety 
of Nelfinavir administered before and during RT in patients with rectal 
adenocarcinoma. We also explored the feasibility of incorporating biomarkers of RT 
that could be used in efficacy studies and the ability of p-CT and DCE-MRI to detect 
changes in tumor perfusion during therapy.   
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Patients and Methods  
Study design  
SONATINA was a non-randomized, open-label clinical trial (EudraCT number: 2010-
020621-40) to establish the safety of nelfinavir with hypofractionated pelvic RT. The 
primary outcome was measured by the occurrence of any grade 3 or higher toxicities 
(Common Terminology Criteria for Adverse Events (CTCAE), version 4.0) within 28 
days of the last fraction of RT.  Since the primary outcome was the safety of this 
novel combinatorial therapy, there was no control group.  Secondary outcomes 
included radiological response of primary tumor at 8 weeks post RT, feasibility of 
measuring a tissue biomarker (TCD) in pre-treatment biopsies and biopsies taken 7 
days after RT, and feasibility of using dynamic imaging to evaluate tumor perfusion. 
Ethical approval was obtained from National Research Ethics Service Committee 
South Central (reference 10/H0604/61). Key inclusion criteria were patients with 
histologically-proven adenocarcinoma of the rectum, radiological evidence of M1 
disease, suitability for short-course RT as primary treatment (determined by 
Colorectal Tumor Board), ECOG performance status 0-2, DQGDJH\HDUV
Exclusion criteria included previous pelvic RT, recent severe cardiac disease or 
operable primary tumor (in opinion of Tumor Board).  
Treatment 
Patients received 7 days of oral Nelfinavir (1250 mg bd) before RT and a further 7 
days of nelfinavir during RT.  This dose of nelfinavir has been shown to consistently 
reduce levels of Akt phosphorylation in peripheral-blood mononuclear cells in 
patients with cancer (29). Compliance logs were used to check that all doses were 
taken as prescribed.  The total dose of RT was 25 Gy, delivered in 5 Gy fractions on 
5 days during a 7-day period as a single-phase treatment prescribed to the 
International Commission on Radiation Units (ICRU) Reference Point.  The dose 
constraints were set such that at least 99% of the planning target volume (PTV) 
should receive 95% of the prescription dose. The PTV maximum was no more than 
107% of the prescribed dose to the ICRU reference point.  For all patients, 3-7 
photon beams (6 or 15 MV) were used, with the entire plan displayed in physical 
dose.  Conformal RT plans were reviewed by a RT quality assurance panel 
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(independent clinician, radiographer, physicist) prior to delivery of the first fraction.  
Verification imaging by cone beam CT to localize the treatment volume was required 
prior to every fraction for the first 3 fractions.  In order to treat metastases, patients 
were permitted to commence systemic chemotherapy 14 days after completion of 
RT. 
Details of procedures  
Patients underwent MRI of the pelvis at baseline and 8 weeks after completion of RT 
for assessment of Tumor Regression Grade (mrTRG) according to a recognized 
scoring system(30).  As previously published(30), patients with mrTRG score of 1-3 
RQ05,VFDQZHUHFODVVLILHGDVKDYLQJµJRRGPU75*VFRUH¶and patients with mrTRG 
VFRUHRIRUZHUHFODVVLILHGDVKDYLQJµSRRUPU75*VFRUH¶Anonymised scans 
were assessed by 2 independent radiologists; agreement was evaluated by weighted 
Kappa statistic. In cases of discrepancy, scans were assessed by a third 
independent radiologist and consensus derived.  
Dynamic imaging 
In order to explore changes in tumor perfusion induced by protocol therapy, DCE-
MRI and p-CT scans of the rectum were incorporated at 3 timepoints: before 
commencement of nelfinavir, the day before commencement of RT (i.e. Day 7 of 
nelfinavir) and on the last day of treatment (before the RT fraction was delivered). 
Mean p-CT parameters [Blood Flow (BF), Blood Volume (BV) and Mean Transit 
Time (MTT)] and median DCE-MRI parameters (Ktrans, Kep and Ve) scans were 
measured in the tumour volume of interest were and percentage change in these 
values were presented graphically.  
Tissue biomarkers  
 
In diagnostic biopsies and biopsies performed 7 days after completion of RT, TCD 
was measured in digitally scanned hematoxylin and eosin stained slides using an 
automated scanning system (Aperio XT, Aperio Technologies, Vista CA) at 200x 
magnification(27, 28).  In cases where there was variation in TCD across the 
specimen, we used the area of tumor with highest TCD, as we have previously 
reported and correlated with clinical outcomes(27). Immunohistochemistry was 
carried out on pre-treatment rectal biopsy specimens using the Leica Bond-Max 
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automated immunostainer (Leica Microsystems, Wetzlar, Germany) on 5 µM 
sections cut from formalin-fixed paraffin-embedded tissue.  As an indicator of 
baseline characteristics, pre-treatment biopsy sections were stained for the following 
biomarkers: CAIX, HIF- 1D, Phospho-PRAS40 (see Supplementary Information).  
 
Statistical analyses 
The Wilcoxon Signed Rank test was used to determine pairwise differences for non-
parametric data and the paired 6WXGHQW¶Vt-test was used to determine pairwise 
differences for parametric data. 
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Results 
Recruitment, compliance and toxicities 
From April 2011 to August 2013, 19 patients were screened and 10 patients 
recruited (Figure 1; Table 2).  All patients completed RT as per protocol. Compliance 
logs revealed that one patient missed one dose of nelfinavir and another patient 
missed two doses of nelfinavir.  
There were no Grade 4 toxicities. Two patients stopped taking nelfinavir early 
because of toxicity: one on day 13 of treatment because of an allergic rash (grade 3, 
probably related), the other on day 4 due to vomiting (grade 3, possibly related but 
patient had pre-existing partial gastric outlet obstruction). Additionally, 5 patients had 
Grade 3 toxicities within 28 days of RT (Table 3).  One patient was admitted to 
hospital with Grade 3 diarrhea 23 days after completion of RT and nelfinavir, which 
was 7 days after commencement of Oxaliplatin and 5FU chemotherapy. This event 
was considered to be related to chemotherapy and possibly related to RT, but 
unrelated to nelfinavir. Another patient developed Grade 3 diarrhea 4 days after 
completion of nelfinavir and RT; this event was considered to be causally related to 
protocol therapy. Another patient had Grade 3 perianal pain due to hemorrhoids, 
probably related to RT.  
With regard to laboratory values, one patient developed Grade 3 lymphopenia on the 
last day of protocol therapy; this persisted on a blood test one month following 
completion of therapy.  The total white cell count was normal and the patient had no 
evidence of active infection. A number of Grade 1 or 2 abnormalities in liver function 
tests were observed within 3 months of therapy, likely to be related to liver 
metastases or chemotherapy (Supplementary Table 1).  One patient had 
hyponatremia (Grade 3) which preceded protocol therapy, and worsened transiently 
during an episode of diarrhea after RT.  Since a known side effect of nelfinavir is 
diabetes mellitus, fasting glucose was checked during treatment and follow-up. 
Three patients had Grade 1 or 2 hyperglycemia after 7 days of nelfinavir; blood 
glucose was normal on subsequent testing 28 days after completion of therapy.  
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Radiological responses 
Using a recognized scoring system(30), inter-observer agreement between two 
independent radiologists was good, with weighted kappa score of 0.79. Of 9 patients 
who completed MRI scans of the pelvis 8 weeks after completion of nelfinavir and 
RT to assess mrTRG response of the primary tumor, 5 SDWLHQWVH[KLELWHG³JRRG´
tumor regression according the definitions of the scoring system(30)7DEOHDQG
6XSSOHPHQWDU\)LJXUH,WVKRXOGEHQRWHGWKDWDVGLVFXVVHGLQWKH,QWURGXFWLRQD
PDMRUEHQHILWRIWKHWUHDWPHQWVWUDWHJ\DGRSWHGLQWKLVFOLQLFDOWULDOZDVWKDWSDWLHQWV
ZHUHSHUPLWWHGWRFRPPHQFHIXOO-GRVHV\VWHPLFFKHPRWKHUDS\WRWUHDWPHWDVWDWLF
GLVHDVHDVHDUO\DVGD\VIURPWKHODVWIUDFWLRQRI57DVGRFXPHQWHGLQ7DEOH  
Dynamic Imaging 
All 10 patients in the study successfully completed p-CT scans at 3 time points 
(Supplementary Figure 2). The pCT scans for one patient (patient 7) were excluded 
from analysis for technical reasons.  Nine patients underwent DCE-MRI scanning at 
all 3 timepoints. One patient (patient 1) did not undergo the second DCE-MRI scan 
because of vertigo. A further 3 scans were excluded from analysis because of 
inadequate contrast enhancement or contrast extravasation.   
Analyzing the percentage change in perfusion parameters between the pre-
treatment scans (scan 1) and the scan on the 7th day of nelfinavir (scan 2), the 
median BF was 37.3 at scan 1, and 43.9 at scan 2 (non-significant by Wilcoxon 
Signed Rank test). There were also no statistically significant changes in BV or MTT 
demonstrated between scans 1 and 2 (non-significant by Wilcoxon Signed Rank 
test).   
Between the p-CT on the 7th day of nelfinavir (scan 2) and the scan at the end of RT 
(scan 3), an increase in BF in association with a decrease in MTT was observed in 8 
of 9 evaluable patients (Figure 2A).  A significant median 30% increase in BF 
(p=0.01, Wilcoxon Signed-Rank test) and a 29% median decrease in MTT was 
observed (p=0.01, Wilcoxon Signed-Rank test) on p-CT from scan 2 to scan 3 
(Supplementary Table 2). 
Between the DCE-MRI on the 7th day of nelfinavir (scan 2) and the scan at the end of 
RT (scan 3), an increase in median Ktrans  was demonstrated in all 7 evaluable 
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patients  (Figure 2B and Supplementary Table 3).  Between scans 2 and 3, there 
was a 42% (0.08 min-1) mean increase in median Ktrans and a 13% (0.07) mean 
increase in median Ve. (p=0.03 and p=0.02 respectively, 6WXGHQW¶VW-test).  
Tissue biomarkers 
TCD was evaluable in all of the pre-treatment rectal biopsy specimens and in 9 out 
of 10 post-radiotherapy biopsy specimens (Figure 2C). The median TCD decreased 
from 24 (interquartile range from 13 to 45) at baseline to 9 (interquartile range 3-16) 
on post-treatment biopsies.  One of the post-tUHDWPHQWELRSVLHVFRQWDLQHGDGHQRPD
FHOOVEXWQRPDOLJQDQWFHOOVZKLFKZDVDWWULEXWHGWRVDPSOLQJHUURUWKLVVDPSOHZDV
QRWLQFOXGHGLQDQDO\VHV 
The sample size was not adequate to study potential relationships between somatic 
or immunohistochemical analyses (Supplementary Figure 3) at baseline and 
radiological response 8 weeks from the end of RT, but these data are presented in 
Table 4 and Supplementary Tables 4-6 since they may assist in the design of future 
studies of this treatment combination. Of note, 7 out of 10 tumours had KRAS 
mutation.   
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Discussion 
Nelfinavir has been shown to inhibit Akt at standard clinical doses and to cause 
radiosensitization in vivo(17).  This early-phase trial was designed to study the safety 
of nelfinavir with hypofractionated pelvic RT, and to develop both tissue and imaging 
biomarkers of the potential efficacy of this combinatorial therapy for use in future 
studies.  We have demonstrated that the combination of nelfinavir and 
hypofractionated pelvic RT is well tolerated in patients with advanced rectal cancer. 
Advancement of nelfinavir as a radiosensitizer  
Although the sample size in this study was not sufficient to make any definite 
conclusions about response rate, the proportion of good mrTRG in the study 
presented here compares favorably to LCCRT for locally advanced rectal cancer.  In 
one large UK study, the rate of good mrTRG for LARC was 50% overall(30) and for 
7Ftumors only 33%.  This compares to 56% in the study presented here, in which 
60% patients had T4 tumors and 70% had a KRAS mutation. It should be noted that 
4 of the patients with good mrTRG score had 3-6 weeks of chemotherapy between 
the end of RT and MRI assessment.  Although systemic therapy may have 
contributed to the clinical response rates observed, the ability to administer full-dose 
systemic therapy soon after RT appears to be a promising treatment strategy with 
regard to clinical response rates.  The efficacy of hypofractionated RT followed by 
systemic chemotherapy in comparison to standard chemo-radiation is currently being 
tested in the international, multi-centre, randomised trial, RAPIDO 
(NCT01558921)(31).   
Importantly, the SONATINA study is the first clinical trial to assess the safety of 
nelfinavir and RT without the confounding effect of concurrent chemotherapy (see 
Table 1).  A previous study of nelfinavir and long course chemo-radiotherapy with 
capecitabine resulted in unacceptable levels of Grade 3 hepatotoxicity(32), which 
may have been attributable to a drug interaction between chemotherapy and 
nelfinavir.  Similarly, in a study of concurrent nelfinavir, temozolomide and RT for 
patients with glioma, 3 patients experienced dose-limiting Grade 3 transaminase 
elevation(33).  In our study, we observed 3 Grade 3 toxicities which were considered 
to be possibly or probably related to nelfinavir: diarrhea, drug rash and lymphopenia. 
Of these, only the drug rash was a dose-limiting toxicity.  Consistent with the 
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published toxicities of hypofractionated pelvic RT without nelfinavir(34-36), our 
conclusion is that the addition of nelfinavir to hypofractionated pelvic RT is well 
tolerated.  Importantly, hepatotoxicity was not observed in our study (see Table 1, 
Supplementary Information).  It should be noted that 7 out of 10 patients treated in 
the clinical trial reported here had low rectal tumors (Table 2); we propose that future 
studies including patients with mid and high rectal tumors should carefully document 
toxicities to ensure the safety of treating larger volumes of small intestine with RT. 
 Dynamic imaging as a biomarker of efficacy 
In addition to intrinsic radiosensitization, we have shown previously that nelfinavir 
caused sustained improvements in tumor perfusion and reduction in hypoxia in a 
mouse xenograft model after 5-14 days of treatment(18).  We therefore evaluated 2 
imaging biomarkers to measure potential changes in perfusion during nelfinavir 
therapy in patients with cancer: p-CT and DCE-MRI.  Although no changes were 
observed from 7 days of the trial drug, our study showed a 30% increase in mean BF 
using p-CT and a 42% mean increase in median ktrans using DCE-MRI scans during 
RT and nelfinavir.  The intra-subject coefficient of variation for BF in colorectal 
tumors has been reported to be in the range 14-23%(37, 38) and studies suggest 
that the coefficient of variation for ktrans measurements in tumors using DCE-MRI is of 
the order of 20%(39, 40).  In our study, the consistency between the findings of the 2 
imaging modalities adds substantial support to the observation of increased tumor 
perfusion.  Although ktrans can be affected by permeability, our findings from p-CT as 
well as DCE-MRI suggest increased blood flow from the combination of nelfinavir 
plus RT. 
 
Since there was no control group (i.e. no nelfinavir) in this early-phase trial designed 
to show the safety of protocol therapy, it is not possible to differentiate the effect of 
RT on blood flow from the effect of nelfinavir plus RT in the data from our imaging 
biomarkers.  Previous studies of LCCRT have demonstrated increases in tumor 
perfusion parameters during the initial weeks of RT(22, 41) followed by subsequent 
decreases in tumor perfusion after completion of therapy(21, 24, 42-44). Our findings 
are consistent with previously reported increases in median ktrans between baseline 
and the fifth fraction of hypofractionated RT for locally advanced rectal cancer(23).   
In order to ascertain whether the significant changes we have observed are due to 
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RT or due to the combination of nelfinavir with RT, we propose that phase II studies 
of the efficacy of nelfinavir-RT versus RT alone should incorporate imaging 
biomarkers of blood flow.   
 
Tissue biomarkers 
At present, tissue biomarkers for the selection of patients for a treatment strategy 
including a novel radiosensitizing drug do not exist.  Visual estimation of the 
tumor:stroma ratio has been shown to be prognostic for patients with localized colon 
cancer (45), but this has not been studied in patients with metastatic rectal cancer 
scheduled to receive RT.  We sought to develop a reproducible, quantitative tissue 
biomarker of potential radiosensitization for use in future clinical trials. We have 
previously assessed TCD in pre-treatment biopsy specimens and resected 
tumors(27, 28), and in the study presented here we assessed the feasibility of 
measuring TCD in both pre-RT and post-RT biopsy samples obtained at endoscopy. 
Our results are in favour of the hypothesis that the addition of nelfinavir to 
hypofractionated RT may result in additional tumor cell kill compared to RT alone.  
Compared to our previous study of 45 rectal cancer patients who received 25 Gy in 5 
fractions of RT to the pelvis followed by surgery 7 days after the end of 
radiotherapy(28),  whose TCD values ranged from 14 to 46, the range of post-
treatment TCDs in this study was 1 to 21.  Based on these findings, we conclude that 
TCD can be measured in biopsies taken pre- and post-RT.  Although TCD could be 
developed further as a biomarker of radiosensitizing drugs for use in prospective 
clinical trials, there are limitations in assessing TCD from biopsies due to differences 
in sampling techniques.  Larger, correlative studies with imaging such as mrTRG are 
warranted.  
Conclusions 
This study has shown that the combination of nelfinavir and hypofractionated RT for 
locally advanced rectal cancer is well tolerated and that this novel treatment strategy 
can be followed by combination chemotherapy as early as 14 days after RT to treat 
metastatic disease.  Consistent with previous studies of RT, nelfinavir plus 
hypofractionated RT significantly increased mean blood flow to tumor compared to 
baseline values.   The tissue biomarker TCD can be measured on biopsies taken 
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before and after RT; it is a candidate biomarker for systematic development for 
assessing potential radiosensitizing drugs prior to phase II evaluation. 
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Table 1: Summary of clinical studies investigating nelfinavir in combination with chemo-radiation therapy 
Study 
[reference 
number] 
Tumour type No. of 
patients 
Treatment 
Regime 
Endpoints G3/4 toxicities 
observed 
Dose 
Limiting 
Toxicities 
Response 
rates on 
CT scans 
Brunner et 
al. (29) 
Pancreatic 
adenocarcinoma  
(Unresectable or 
borderline 
resectable) 
12 NFV 1250 mg bd 
3 d before and 
concurrent with : 
59.4 Gy pancreas  
DL1  Cisplatin 30 
mg/m² 
Gemcitabine 200 
mg/m² D1,8,22, 29 
(n=5) 
DL2 Cisplatin 30 
mg/m² 
Gemcitabine 300 
mg/m² D1,8,22,29 
(n=5) 
DLT 
RECIST 
(CT) 
response 
PET 
response 
Resection 
rate 
G3 leukopenia (4) 
G3 neutropenia (3) 
G3 thrombocytopenia (2) 
G3 Nausea/vomiting (2) 
G3(1) G4 (1) 
Transaminase  
G3 Bilirubin (2) 
G3 Alkaline phosphatase 
(1) 
G3(2) G4 (1) Infection 
G3 upper GI  
(1) at DL1 
G3 nausea 
and vomiting 
(1) at DL2 
5/10 PR,   
6/10 
resection, 
5/9 CR 
Rengan et 
al. (46) 
Non Small Cell 
Lung Cancer 
(Unresectable 
Stage IIIA/IIIB) 
16 NFV 7-14 d before 
and concurrent 
with: 
66.6 Gy in 38#   
involved field + 
Cisplatin 50 mg/m² 
D1, 8, 29, 36 
Etoposide 50 
mg/m² D1-5 , 29-
36 
DL1: NFV 625 mg 
bd (n=5) 
DL2 : NFV 1250 
mg bd (n=8) 
DLT 
CT 
response 
PET 
response 
G3 esophagitis (4) 
G3 pulmonary toxicity (1) 
G3 leukopenia (3) 
G3 anemia (2) 
G3 thrombocytopenia (2) 
G3 upper GI (3) 
G3 hypotension (3) 
G3 fatigue (2) 
G4 leukopenia (6) 
G4 thrombocytopenia (1) 
None 4/12 CR,  
7/12 PR, 
1/12 SD   
Buijsen et 
al. (32) 
Locally 
advanced rectal 
adenocarcinoma 
12 50.4 Gy in 28 # 
pelvis and 
Capecitabine  825 
mg/m² concurrent 
with NFV: 
DL1 NFV  750 mg 
bd (n=5) 
DL2 NFV1250 mg 
bd (n=3) 
DL3  NFV 100 mg  
bd (n=3) 
DLT 
pCR 
TRG 
G3 transaminase (2) 
G3 cholangitis (1) 
G3 ileus 
G3  diarrhea (2) 
G4 post-op wound 
complication (1) 
G3  diarrhea 
(2) at DL2 
G3 
transaminase 
(2) 
G3 
cholangitis 
(1) 
G3 ileus 
G4 post-op 
wound 
complication 
(1)  
At DL3 
pCR 3/11 
(27%) 
Good TRG  
4/11 
Alonso ±
Basanta 
et al. (33) 
Glioblastoma 
(post-op) 
21 NFV 7-10 days 
before and 
concurrent with: 
60 Gy in 30#  GTV 
and  
Temozolomide 75 
mg/m2 od 
DL1 NFV  625 mg 
bd (n=3) 
DL2 NFV 1250 mg 
bd (n=18) 
DLT 
PFS 
OS 
Diarrhea (1) 
Transaminase (8) 
Bilirubin (1) 
Alkaline phosphatase (1) 
Lymphopenia (2) 
G3 
hepatotoxicity 
(3) 
G3 diarrhea 
(1) at DL2 
Median 
PFS 7.2 
months 
Median OS 
13.7 
months 
Abbreviations used: CR, Complete Response; CT, Computed Tomography; DL, dose level; DLT, Dose Limiting 
Toxicity; G3/4, Grade 3/4; NFV, Nelfinavir; OS, Overall Survival; pCR, pathologic Complete Response; PFS, 
Progression Free Survival; PR, Partial Response; PET, Positron Emission Tomography; SD, Stable Disease; TRG, 
Tumour Regression Grade; 
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Table 2: Clinical and Radiological Patient Characteristics at Baseline 
 
  SONATINA patients (N=10) 
Characteristic No. % 
Age(years)     
  Median 65 
  Range 45-81 
Gender     
  Male 5 50 
  Female 5 50 
ECOG Performance 
Status 
    
  0 4 40 
  1 6 60 
Sub-site of tumor in 
rectum 
    
  Low 7 70 
  Mid 2 20 
  Upper 1 10 
MRI defined T-stage     
  T3 4 40 
  T4 6 60 
MRI defined N-stage     
  N0 2 20 
  N1 3 30 
  N2 5 50 
Sites of metastatic 
disease (CT) 
    
  Liver 8   
  Distant lymph nodes 5   
  Lung 6   
  Other 1   
Abbreviations used: MRI, magnetic resonance imaging; CT, computed 
tomography. 
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Table 3: Toxicities observed up to 28 days from the last fraction of RT 
 
No. of toxicities 
Toxicity CTCAE Grade 0-2 CTCAE Grade 3 
{Nelfinavir causality} 
CTCAE Grade 4 
Anemia 1 (1 patient) 0 0 
Anorexia 2 (2 patients) 0 0 
Diarrhea 7 (6 patients) 2 (2 patients) 
{probably related, 
definitely not related} 
0 
Fatigue 8 (7 patients) 0 0 
Fever 1 (1 patient) 0 0 
Gastrointestinal ± other 7 (5 patients) 0 0 
Hyperglycemia  
(fasting glucose) 
3 (3 patients) 0 0 
Hyponatremia 0  1 (1 patient) 
{probably not related} 
 0 
Lymphopenia 2 (2 patients) 2 (1 patient) 
{possibly related,   
definitely not related} 
0 
Nausea/vomiting 12 (5 patients) 1 (1 patient) 
{possibly related} 
0 
Other 8 (7 patients) 0 0 
Pain 3 (3 patients) 0 0 
Peripheral neuropathy 2 (2 patients)     
Proctitis/perianal pain 3 (3 patients) 1 (1 patient) 
{probably not related} 
0 
Rash 4 (4 patients) 1 (1 patient) 
{probably related} 
0 
Urinary symptoms 5 (3 patients) 0  0 
Total 68 8 (7 patients) 0 
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Table 4: Tumour response on MRI 8 weeks post therapy (mrTRG score) for individual patients in 
relation to baseline characteristics and number of cycles of chemotherapy administered. 
Patient 
number 
Baseline 
MRI 
stage 
KRAS  
mutation 
status 
HIF1-alpha 
expression 
at baseline  
CAIX 
expression 
at baseline 
Phospho-
PRAS40 
Expression 
at baseline 
No. weeks of 
oxaliplatin-
fluouracil 
chemotherapy 
between end 
of RT and MRI 
mrTRG 
score 
1 T3b N2 Wild-type  negative positive negative 6 good 
2 T4 N2 Mutant 
(G12V) 
negative negative negative 6 poor 
3 T3a N2 Wild-type positive negative positive 6 good 
4 T3b N2 Mutant 
(G12A) 
Not 
evaluable 
positive negative 6 poor 
5 T3a N2 Mutant 
(G12S) 
positive negative negative 3 good 
6 T4 N2 Mutant 
(G12V) 
negative negative negative 3 poor 
7 T4 N2 Wild-type negative positive positive 4 poor 
8 T4 N2 Mutant 
(G12V) 
negative Not 
evaluable 
Not 
evaluable 
4 good 
9 T4 N1 Mutant 
(G12C) 
positive positive  positive None good 
10 T4 N2 Mutant 
(G13A) 
positive negative negative None N/A 
Abbreviations used: mrTRG, Tumour Regression Grade on MRI 8 weeks post radiotherapy; Ox/MDG, 
Oxaliplatin and Modified de Gramont; CAPOX, Capecitabine and Oxaliplatin 
 
